Online First Nr279

Psychiatr. Pol. ONLINE FIRST Nr 279: 1–15
 
Published ahead of print 20 May 2022
 
 
Katarzyna Gibek, Tomasz Sacha

FREE POLISH FULLTEXT:

FREE ENGLISH FULLTEXT:
Assessment of factors affecting the mental condition of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
 
Summary
Aim. The aim of the study was to make a general assessment of mental health, including signs of somatization, depression, anxiety, and functional disorders, in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) and to assess the impact of factors such as the duration of the disease, side effects of therapy, age, and gender on the occurrence of the above-mentioned disorders. Another goal was to identify patients at risk of developing mental disorders.
Method. The study involved 91 patients and was conducted at the Hematology Clinic of the University Hospital in Krakow. The following questionnaires were used to assess mental health: survey created by the author, David Goldberg’s questionnaire GHQ-28, and the fourdimensional 4DSQ, measuring four dimensions of the mental condition.
Results. The average level of the mental condition of the studied group was demonstrated. 29 people with mental disorders were identified. Women and people living alone obtained worse results in almost all dimensions of the questionnaires. The analysis revealed that factors such as age, number of side effects and gender significantly affect mental disorders in the studied group. A significant and positive correlation has been found between the number of side effects and the presence of somatization signs. Mediocre correlations occurred between age and mental disorders and all dimensions of the GHQ-28.
Conclusions. The obtained results indicate that attempts should be made to reduce side effects among CML patients. Visiting the psychologist to work on the acceptance of the disease, psychoeducation, behavioral therapy, and contact with a psychiatrist to consider the introduction of pharmacotherapy is recommended. All of these methods may improve a patient’s quality of life.
 
 

ISSN 0033-2674 (PRINT)

ISSN 2391-5854 (ONLINE)


Psychiatria Polska
is an Open Access journal:
Creative Commons: CC-BY
SHERPA RoMEO:
Blue


Zadanie finansowane
w ramach umowy
nr 739/P-DUN/2018
ze środków MNiSW
przeznaczonych
na działalność
upowszechniającą naukę


KRW PTP dziękuje 
firmie PPL – Koral – J.Koral sp.j.
za wsparcie finansowe 
udzielone w 2020 roku



Inne strony PTP:
Other PTP websites:

www.psychiatria.org.pl
www.psychiatriapsychoterapia.pl

www.archivespp.pl
www.psychoterapiaptp.pl

Psychiatria Polska
INDEXED IN:
Thomson Reuters Master List
Science Citation Index Expanded
Journal Citation Reports
(Impact Factor 1,596)

Medline/Index Medicus
PubMed/LinkOut
MNiSW (100 pkt)
Scopus/SCImago
CiteScore 2,4
(SJR 0,414; SNIP 0,707)
EMBASE/Excerpta Medica
PsycINFO, EBSCO,
Index Copernicus
Erih Plus, Cochrane Library
CrossRef/DOI

We recommend:

Pharmacological Reports

 


KONTAKT Z REDAKCJĄ - wyłącznie e-mail: redakcja@psychiatriapolska.pl 

Biuro KRW PTP - prenumeraty, faktury - wyłącznie e-mail: biuro@krwptp.pl 
krwptp.pl